

Harrier (deleter

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work,

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Sedional Identifying Infor	mation	
1. Given Name (First Name) Nilofer	2, Surname (Last Namé) Azad	3. Date 25-January-2019
4. Are you the corresponding author?	Yes No.	Corresponding Author's Name Mark Yarchoan
5. Manuscript Title PD-L1 expression and tumor mutation	al burden (TMB) are indep	endent biomarkers in most cancers
6. Manuscript Identifying Number (if you k	nowit)	
ti da sa		
Sagion 2	ionsideration for Publi	
Did you or your institution at any time rece	eive payment or services from g but not limited to grants, da	a third party (government, commercial, private foundation, etc.) for at a monitoring board, study design, manuscript preparation,
Sequiones (Relevantinancial	adivitesouside the	
Place a check in the appropriate boxes of compensation) with entities as descr	in the table to indicate while the table to indicate while the instructions, Use port relationships that we	ether you have financial relationships (regardless of amount se one line for each entity; add as many lines as you need by re present during the 36 months prior to publication.
Section 4 Intellectual Proper	ity — Patents & Gopyric	ÌΒ
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work? Yes V No



્રાંચના(લો) કે. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Septions of Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Azad has nothing to disclose.
(5//s)(reliforeind) paegleral

Please visit http://www.icmie.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Azad



districted for the

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Vithayathil

3



Sadional Identifying Infor	mation	
1. Given Name (First Name) Teena	2. Surname (Last Name) Vithayathil	3. Date 25-January-2019
4. Are you the corresponding author?	✓ Yes No	
5. Manuscript Title PD-L1 expression and tumor mutation	al burden (TMB) are independent bioma	rkers in most cancers
6. Manuscript identifying Number (if you k	cnow it)	
en er		
Service A The Work Under G	onsideration for Publication	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of inter-	g but not limited to grants, data monitoring	jovernment, commercial, private foundation, etc.) for board, study design; manuscript preparation,
Segiones Edevention of	activities outside the submitted w	odk.
Place a check in the appropriate boxes of compensation) with entities as descr	in the table to indicate whether you have ibed in the instructions. Use one line for port relationships that were present du	e financial relationships (regardless of amount each entity; add as many lines as you need by ring the 36 months prior to publication.
Scalion 4 Intellectual Prope	rty⇔Patents&Gopyrights	
Do you have any patents, whether plan	ined, pending or issued, broadly relevan	t to the work? Yes No



	Statiforn 5). Relationships not covered above
95	Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
	Yes, the following relationships/conditions/circumstances are present (explain below):
	No other relationships/conditions/circumstances that present a potential conflict of interest
	At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
	Santon Disclosure Statement
	Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
	Dr. Vithayathil has nothing to disclose.

Activition and Residently

Please visit http://www.icmie.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



lakerer (nile) ek

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work, Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so,

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Segional	nation				
1. Given Name (First Name) Neeha	2. Surname (Last Name) Zaidi		3. Date 26-January-2019		
4. Are you the corresponding author?	Yes No	Corresponding Author's Name	e		
5. Manuscript Title PD-L1 expression and tumor mutations	al burden (TMB) are indepe	endent biomarkers in most ca	incers		
6. Manuscript Identifying Number (if you k	now.it)				
The state of the s					
Stadion 2: The Work Under G	onsideration for Publi	€GOn			
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes V					
ડાવલમાં કાર્યો Relevant financial	activities outside the	ubmitted work			
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to publication . Are there any relevant conflicts of interest? Yes V					
Specificativa). Intellectual Proper	ty-Patents&Copyrid	J iis			
Do you have any patents, whether plan	ned, pending or issued, br	oadly relevant to the work?	Yes 🗸 No		



Strictures Relationshipsnot-covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
टानमं(ल्याक्षर) Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Selvenoi englacided.

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



distributions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts,



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena; that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Albacker



Specifican 1	nation					
Given Name (First Name) Lee	2. Surname (Last Name) Albacker	3. Da 25-J	ate anuary-2019			
4. Are you the corresponding author?	Yes V No	Corresponding Author's Name Elizabeth M. Jaffee				
5. Manuscript Title PD-L1 expression and tumor mutational burden (TMB) are independent biomarkers in most cancers						
6. Manuscript Identifying Number (if you kr	now it)					
en e						
Startifon 2: The Work Under Co	onsideration for Public	elijon.				
Did you or your institution at any time receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)? Are there any relevant conflicts of interest? Yes. Vivo						
Service Falls of						
namanayen.	activities outside the s					
Place a check in the appropriate boxes in of compensation) with entities as descriptioning the "Add +" box. You should repair to the second state of interest	bed in the instructions. Us port relationships that wer	e one line for each entity; add as	many lines as you need by			
Are there any relevant conflicts of intere	st?					
Section // Intellectual Proper	ty - Patents & Copyrig	ltte				
Do you have any patents, whether plant	ned, pending or issued, br	oadly relevant to the work?	Yes 🔽 No			



Side (On 5) Relationships act covered above
Majoriem jamoasus as reintona
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
Employee of Foundation Medicine Inc.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Sention 6 Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Albacker reports he is an employee of Foundation Medicine Inc.,
(Avaluation and Essablation

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Albacker



dichellenterit

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work,

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: Agrant from an entity, generally (but not always) paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes.

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Frampton



Saletjel; i. Identifying/inform	ation	
Given Name (First Name) Garrett	2. Surname (Last Name) Frampton	3. Date 25-January-2019
4. Are you the corresponding author?	✓ Yes No	
5. Manuscript Title PD-L1 expression and tumor mutationa	l burden (TMB) are independent biomarker	's in most cancers
6. Manuscript Identifying Number (if you kn	ow it)	
A CONTROL OF THE PROPERTY OF THE CONTROL OF THE CON	the state of the s	
Section 2. The Work Under Go	onsideration for Publication	
Did you or your institution at any time recei any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not limited to grants, data monitoring boar	rnment, commercial, private foundation, etc.) for d, study design, manuscript preparation,
Seerion ड Relevant financial त	activities outside the submitted work	G
of compensation) with entities as describ clicking the "Add +" box, You should rep	n the table to indicate whether you have fin bed in the instructions. Use one line for each ort relationships that were present during	h entity; add as many lines as you need by
Are there any relevant conflicts of interes	st?	
Section 4 Intellectual Propert	y—Patents&Copyrights	
Do you have any patents, whether plann	ed, pending or issued, broadly relevant to t	the work? Yes No



Seation 5 Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
Employee of Foundation Medicine and a shareholder of Roche Holdings AG
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.
Discoura Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Frampton reports and Employee of Foundation Medicine and a shareholder of Roche Höldings AG.

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form,



The Willer Conf.

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment. supplied by the entity, travel paid by the entity, writing assistance; administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Seeken l	nation				
1. Given Name (First Name) Karthikeyan	2. Surname (Last Name) Murugesan	3. Date 25-Janua	ry-2019		
4. Are you the corresponding author?	✓ Yes No				
5. Manuscript Title PD-L1 expression and tumor mutationa	al burden (TMB) are independent	oiomarkers in most cancers			
6. Manuscript identifying Number (if you k	now (t)				
Segulore Carameter Security					
Did you or your institution at any time rece	onsideration for Publication	party (government, commercial, n	rivate foundation, etc.) for		
any aspect of the submitted work (including statistical analysis, etc.)?	but not limited to grants, data moni-	toring board, study design, manu	script preparation,		
Are there any relevant conflicts of interest? Yes V.No.					
Stanting Relevant financial	activities outside the submit	ted work.			
Place a check in the appropriate boxes i of compensation) with entities as descri	in the table to indicate whether yo	ou have financial relationships	(regardless of amount		
clicking the "Add +" box. You should rep	port relationships that were prese	nt during the 36 months pri	or to publication.		
Are there any relevant conflicts of intere	est? Yes No				
Sealion के IntellectualProper	ty Patents & Copyrights				
Do you have any patents, whether plant	ned, pending or issued, broadly re	levant to the work?	. No		



S(এর্ব্রাল)র 5) Relationshipsmot covered above	
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?	
Yes, the following relationships/conditions/circumstances are present (explain below):	
No other relationships/conditions/circumstances that present a potential conflict of interest	
Is an employee of Foundation Medicine.	
e. Burgarian de la companya de la comp La companya de la companya del companya de la companya de la companya del companya de la companya del companya del companya de la companya del companya del companya de la companya	
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements	ì.
On occasion, journals may ask authors to disclose further information about reported relationships.	
ञ्चनर्थिशाः Disclosure Statement	邓 安公社
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.	
Dr. Murugesan reports and is an employee of Foundation Medicine.	
i. Por esta de la composição	

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.

Murugesan



Institute (

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Yarchoan



ાચલશાંબાર ! ldentifying infor	mation				
1. Given Name (First Name) Mark	2. Surna Yarchoa	ime (Last Name) an			3, Date 25-January-2019
4. Are you the corresponding author?	Yes	✓ No	Correspo	inding Aut	hor's Name
5: Manuscript Title PD-L1 expression and tumor mutation	nal burden ((TMB) are indep	pendent bio	markers i	n most cancers
6. Manuscript Identifying Number (if you	know it)				
Section 2 The Work Under	Considera	tion for Publ	ication		
Did you or your institution at any time rec any aspect of the submitted work (includir statistical analysis, etc.)?	eive paymer ng but not lin	nt or services from nited to grants, c	m a thìrd part lata monitori	y (governr ng board,	nent, commercial, private foundation, etc.) for study design, manuscript preparation,
Are there any relevant conflicts of inte	rest?	Yes 📝 No			
Place a check in the appropriate boxes of compensation) with entities as descricking the "Add +" box, You should re Are there any relevant conflicts of intellif yes, please fill out the appropriate in	in the table ribed in the eport relation rest?	e to indicate when the instructions. Upon that we want to have the week the week to be the week	hether you l	nave finar for each o	ncial relationships (regardless of amount entity; add as many lines as you need by the 36 months prior to publication.
Name of Entity	Grant?		on-Financia Support?	Other	Comments
Merck & Co	7				1990 - No. 1991 - Marian Sanara S
Bristol-Myers Squibb	✓				Provide the Control of the Control o
Exelixis	.: 			\checkmark	Scientific advisory board (uncompensated)
Genentech/Roche				V	I am a Co-Principal Investigator of a clinical trial supported by the Cancer Therapy Evaluation Program (CTEP), utilizing agents provided by Genentech/Roche
Eisai				V	Scientific advisory board



Section 4. Intellectual Property = Patents & Copyrights
Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo
देशवर्गिका हैं। Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Disdosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Dr. Yarchoan reports grants from Merck & Co, grants from Bristol-Myers Squibb, grants and other from Exelixis, other from Genentech/Roche, other from Eisai, outside the submitted work; .
Evalue(Invantilazidiban)
Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form



delajantegist

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company,



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent:



Service	ormation				
Given Name (First Name) Elizabeth		me (Last Nar	ne)		3. Date 25-January-2019
4. Are you the corresponding author?	Yes	No			
5. Manuscript Title PD-L1 expression and tumor mutation		ГМВ) are in	dependent bio	markers in	most cancers
6. Manuscript identifying Number (if yo	u know it)				
Signation is the Work Under			Is Is		
	eceive payment ling but not lim	t or services	from a third part ts, data monitöri	ty (governmi ing board, st	ent, commercial, private foundation, etc.) for udy design, manuscript preparation,
Spaining Relevant financi	alactivities	outside'i	hesubmitte	dwork	
Place a check in the appropriate boxe of compensation) with entities as described the "Add +" box. You should	cribed in the	instruction	is. Use one line	for each er	tial relationships (regardless of amount nitty; add as many lines as you need by 26 months prior to publication.
Are there any relevant conflicts of int If yes, please fill out the appropriate i	erest? 🗸 Y	es 🔲 t	No:		•
Name of Entity	Grant?	Personal Fees?	Non-Financia	Other?	Comments
Bristol Meyers Squibb	7				partition of the section of the sect
Aduro Biotech	V				And the second s
Roche	✓				
Medlmmune	✓	\checkmark	. 🔲	1	Scientific Advisory Board
Corvus					
Amgen					
Genocea Oncology		V		\checkmark	Advisory Board
ncyte			П		Advisory Board



Name of Entity	Grant?		on-Financial Support?	Other?	Comments	·
DragonFly				V	Scientific advisory board	
CSTONE					Scientific advisory board	
Adaptive Biotech				V	Scientific advisory board	
Sugarion ()						esconium di isonomo
Invellegual	Property = Pate	ints & Copyri	ghts			
Do you have any patents, wheth	•		-		<u> </u>	
If yes, please fill out the appropr Excess rows can be removed by	iate information b pressing the "X" b	elow. If you ha utton.	ve more than:	one entit	y press the "ADD" button to ac	id a row.
Patent ?	Pending? Issue	d? Licensed?	Royalties?	License	⊇? Comments	
PCT/US1996/020802 Title: Allogeneic Paracrine Cytosine Tumor Vaccines:			A V	duro Biote	The Johns Hopkins Univer is entitled to milestone payments and royalty on sales of certain cancer vaccine products	sity
ાં મુંદ્રાં (કાર્યા) કાર્યા (કાર્યા)					PC-107761011 60 12476	& do providi do a una seco
waterment.	osmotcovereda					
Are there other relationships or a potentially influencing, what you	activities that read I wrote in the subi	ers could perce mitted work?	eive to have in	ıfluenced	, or that give the appearance o	of
Yes, the following relationship	os/conditions/circ	:umstances:aré	prësent (expl	lain belov	u)-	
No other relationships/condi	•				•	
At the time of manuscript accept On occasion, journals may ask au	ance, journals will ithors to disclose f	ask authors to urther informa	confirm and, tion about rep	if necessa	ary, update their disclosure sta ationships:	tements.



100		COMPANY OF	MGC98990930				
5 a 1		20,000,000	*45055550000m				ment
250 T	1. 7 to 6 i	6.53 6	p affiliation and				ISSESSES TO STREET
	Section .	Section of the	A-1000000	1 n 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	A CONTRACTOR OF THE PERSON OF	2 1 1 1 1 1	A
950269	75 X S S S S S S S S S S S S S S S S S S	NAME OF THE REAL PROPERTY.	********	****	10 10 11 12	09-11-11:	314121116
3.0		ALC: No services		Versilla experience	n and a second second	State Control of the	

EAZARA Sekukenyan resumman resum

Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.

Dr. Jaffee reports grants from Bristol Meyers Squibb; grants from Aduro Biotech, grants from Roche, grants, personal fees and other from Medimmune, grants from Corvus, grants from Amgen, personal fees and other from Genocea Oncology, other from Incyte, other from DragonFly, other from CSTONE, other from Adaptive Biotech, outside the submitted work; In addition, Dr. Jaffee has a patent PCT/US1996/020802 Title: Allogeneic Paracrine Cytosine Tumor Vaccines, with royalties paid to Aduro Biotech.

der der Gregorian der Gertalle

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



The second of the second

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally (but not always) paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued

Issued: The patent has been issued by the agency.

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent



Sacion Telephones as a			
Identifying Infor	mation		
1. Given Name (First Name) Daniel	2. Surname (Last Name) Laheru		3, Date 28-January-2019
4. Are you the corresponding author?	Yes No	Corresponding Author's Na	me
5. Manuscript Title PD-L1 expression and tumor mutation	al burden (TMB) are indepe	endent biomarkers in most o	cancers
6. Manuscript Identifying Number (if you k	know it)		
THE HOLD IN THE WORLD PROPERTY	ionsideration for Public		
Did you or your institution at any time reco any aspect of the submitted work (includin statistical analysis, etc.)? Are there any relevant conflicts of inter	ig but not limited to grants, da	a third party (government, cor ta monitoring board, study de	mmercial, private foundation, etc.) for sign, manuscript preparation,
Section 3. Relevant financia	self) elle control de la contr	ubmittedwork	
Place a check in the appropriate boxes of compensation) with entities as described the "Add +" box. You should re Are there any relevant conflicts of inter-	ribed in the instructions. Us port relationships that were	e one line for each entity; a	dd as many lines as you need by
Sergion 4. Intellectual Prope	nty — Patents & Copyrig	lit e	
Do you have any patents, whether plan	nned, pending or issued, bro	padly relevant to the work?	Yes 📝 No



Section 5. Relationships not covered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
✓ No other relationships/conditions/circumstances that present a potential conflict of interest
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Signification Disclosure Statement
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
A service of the extreme of the enterior of the extreme of the extreme of the extreme of the enterior of the extreme of the ex

Evelocitor and Pagelons's

Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



iliki idi di di kirik

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes"



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued **issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your patent

Montesion



Sastion । ldentitying Inform	lation.			
1. Given Name (First Name) Meagan	2. Surnai Montesi	ne (Last Name) on	3. Date 28-Januar	y-2019 ⁻
4. Are you the corresponding author?	Yes	✓ No	Corresponding Author's Name Elizabeth M. Jaffee	
5. Manuscript Title PD-L1 expression and tumor mutational	ıl burden (TMB) are indepe	endent bjomarkers in most cancers	
6. Manuscript Identifying Number (if you kr	now it)			
0.00°C-0.000 A-0.00000000000000000000000000000				
Sealen 2 The Work Under G	onsidera	ionstari Public	ailon	
Did you or your institution at any time rece any aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of intere	but not lim	t or services from lited to grants, da l'es	a third party (government, commercial, pr ta monitoring board, study design, manus	ivate foundation, etc.) for cript preparation,
Sadjnica 540 White				20-V-700400
Relevant financial	activities	outside the s	ubmitted work	
Place a check in the appropriate boxes i of compensation) with entities as descri clicking the "Add +" box. You should rep	bed in the port relatio	instructions. Us	e one line for each entity; add as many	lines as you need by
Are there any relevant conflicts of intere	st?	′es ✓ No		
Prodeman				
Intellectual Proper	ty = Pate	uestacobyni	ME.	
Do you have any patents, whether plant	ned, pendi	ng or issued, bro	oadly relevant to the work? Yes	✓ No



Relationshipsnoucovered above
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?
Yes, the following relationships/conditions/circumstances are present (explain below):
No other relationships/conditions/circumstances that present a potential conflict of interest
Employee of Foundation Medicine, Inc.
At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.
Sianiferral
Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.
Meagan Montesion is an employee of Foundation Medicine, Inc.
्राष्ट्रविक्तविक्तविक्तविक्तविक्तविक्तविक्तविक्त
Please visit http://www.icmje.org/cgi-bin/feedback to provide feedback on your experience with completing this form.



distribility.

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.



Identifying information.



The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party — that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check



Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.



Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.



Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

Definitions.

Entity: government agency, foundation, commercial sponsor, academic institution, etc.

Grant: A grant from an entity, generally [but not always] paid to your organization

Personal Fees: Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

Non-Financial Support: Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.,

Other: Anything not covered under the previous three boxes

Pending: The patent has been filed but not issued Issued: The patent has been issued by the agency

Licensed: The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

patent



Seekoo	aGlon		
1. Given Name (First Name) Alexander	2. Surname (Last Name) Hopkins		3. Date 28-January-2019
4. Are you the corresponding author?	Yes ✓ No.	Corresponding Author's Na	irrie.
5. Manuscript Title PD-L1 expression and tumor mutational	l burden (TMB) are indepe	endent biomarkers in most	cancers
6. Manuscript Identifying Number (if you kn	ow it)		
and the second s	nama a kina ana a		.
The Work Under Go	onsideration for Public	ation	
Did you or your institution at any time receivany aspect of the submitted work (including statistical analysis, etc.)? Are there any relevant conflicts of interes	but not limited to grants, da	a third party (government, co ta monitoring board, study de	mmercial, private foundation, etc.) for esign, manuscript preparation,
Spaniferical Relevant financial त	ngtivitiesoutside(hes	wowitedwork	
Place a check in the appropriate boxes in of compensation) with entities as describ clicking the "Add +" box: You should rep Are there any relevant conflicts of interes	o the table to indicate who bed in the instructions. Us ort relationships that wer	ether you have financial rel e one line for each entity; a	idd as many lines as you need by
्री:(वंदेश):}}			3525AV2005200025005305
intellectual Properi	y,≕Patents & Gopyrig	l ite s	
Do you have any patents, whether plann	ed, pending or issued, bro	oadly relevant to the work?	Yes 📝 Nö



A. D. G. (1938 See 2	lionshipsmoteovered		Co-Old Hill Co-Old And San Association and Ass	ranna aran summer egypan (Erphiliteral de Arbeil en municipilitaria de acua est	
Are there other relations		ders could perceive to h	ave influenced, or that giv	e the appearance o	f
<u>·</u>	lationships/conditions/ci	·			
At the time of manuscrip	ot acceptance, journals w	ill ask authors to confirm	nand, if necessary, update out reported relationships:	their disclosure stat	èments.
	osure State ment				
		omatically generate a di	sclosure statement, which	will appear in the b	ox
		·		·	
Please wish http://www.in		k to provide foodback or	NOUS DYPONION ON INC.		

TREND Statement Checklist

Paper	Item	Descriptor					
Section/ Topic	No			Pg#			
Title and Abst	ract						
Title and	1	Information on how unit were allocated to interventions	N/A				
Abstract		Structured abstract recommended	Y	2			
		Information on target population or study sample	Y	6			
Introduction							
Background	2	Scientific background and explanation of rationale	Y	3			
		Theories used in designing behavioral interventions	N/A				
Methods							
Participants	3	Eligibility criteria for participants, including criteria at different levels in					
		recruitment/sampling plan (e.g., cities, clinics, subjects)	Y	6			
		Method of recruitment (e.g., referral, self-selection), including the	Ī				
		sampling method if a systematic sampling plan was implemented	N/A				
		Recruitment setting	Y	6			
		Settings and locations where the data were collected	Y	6			
Interventions	4	Details of the interventions intended for each study condition and how	NT/A /				
		and when they were actually administered, specifically including:	N/A (
		Content: what was given?	ınterv	ention			
		 Delivery method: how was the content given? 					
		 Unit of delivery: how were the subjects grouped during delivery? 					
		 Deliverer: who delivered the intervention? 					
		 Setting: where was the intervention delivered? 					
		 Exposure quantity and duration: how many sessions or episodes or 					
		events were intended to be delivered? How long were they intended to last?					
		Time span: how long was it intended to take to deliver the					
		intervention to each unit?					
		 Activities to increase compliance or adherence (e.g., incentives) 					
Objectives	5	Specific objectives and hypotheses	Y	3			
Outcomes	6	Clearly defined primary and secondary outcome measures	Y	6			
		Methods used to collect data and any methods used to enhance the quality of measurements	Y	6			
		Information on validated instruments such as psychometric and biometric properties	Y	6			
Sample Size	7	How sample size was determined and, when applicable, explanation of any	-				
·		interim analyses and stopping rules	Y	6			
Assignment	8	Unit of assignment (the unit being assigned to study condition, e.g.,	Y	6-7			
Method		individual, group, community)	1	0-7			
		Method used to assign units to study conditions, including details of any	N/A				
		restriction (e.g., blocking, stratification, minimization)	IN/A				
		Inclusion of aspects employed to help minimize potential bias induced due	Y	5			
		to non-randomization (e.g., matching)	<u> </u>				

TREND Statement Checklist

Blinding (masking)	9	 Whether or not participants, those administering the interventions, and those assessing the outcomes were blinded to study condition assignment; if so, statement regarding how the blinding was accomplished and how it was assessed. 	N/A interv	(non vention
Unit of Analysis	10	Description of the smallest unit that is being analyzed to assess intervention effects (e.g., individual, group, or community)	Y	6
		 If the unit of analysis differs from the unit of assignment, the analytical method used to account for this (e.g., adjusting the standard error estimates by the design effect or using multilevel analysis) 	Y	6
Statistical Methods	11	Statistical methods used to compare study groups for primary methods outcome(s), including complex methods of correlated data	Y	6
		Statistical methods used for additional analyses, such as a subgroup analyses and adjusted analysis	Y	6
		Methods for imputing missing data, if used	N/A	
		Statistical software or programs used	Y	6
Deceles				
Participant flow	12	 Flow of participants through each stage of the study: enrollment, assignment, allocation, and intervention exposure, follow-up, analysis (a diagram is strongly recommended) 	N/A	
		 Enrollment: the numbers of participants screened for eligibility, found to be eligible or not eligible, declined to be enrolled, and enrolled in the study 		
		 Assignment: the numbers of participants assigned to a study condition 		
		 Allocation and intervention exposure: the number of participants assigned to each study condition and the number of participants who received each intervention 		
		 Follow-up: the number of participants who completed the follow-up or did not complete the follow-up (i.e., lost to follow-up), by study condition 		
		 Analysis: the number of participants included in or excluded from the main analysis, by study condition 		
		 Description of protocol deviations from study as planned, along with reasons 	N/A	
Recruitment	13	Dates defining the periods of recruitment and follow-up	N/A	
Baseline Data	14	Baseline demographic and clinical characteristics of participants in each study condition	N/A	
		Baseline characteristics for each study condition relevant to specific disease prevention research	N/A	
		Baseline comparisons of those lost to follow-up and those retained, overall and by study condition	N/A	
		Comparison between study population at baseline and target population of interest	N/A	
Baseline equivalence	15	Data on study group equivalence at baseline and statistical methods used to control for baseline differences	N/A	

TREND Statement Checklist

Numbers analyzed	16	Number of participants (denominator) included in each analysis for each study condition, particularly when the denominators change for different outcomes; statement of the results in absolute numbers when feasible	Y	4
		Indication of whether the analysis strategy was "intention to treat" or, if not, description of how non-compliers were treated in the analyses	Y	4
Outcomes and estimation	17	For each primary and secondary outcome, a summary of results for each estimation study condition, and the estimated effect size and a confidence interval to indicate the precision	Y	4
		Inclusion of null and negative findings	Y	4
		 Inclusion of results from testing pre-specified causal pathways through which the intervention was intended to operate, if any 	N/A	
Ancillary analyses	18	Summary of other analyses performed, including subgroup or restricted analyses, indicating which are pre-specified or exploratory	Y	6-7
Adverse events	19	Summary of all important adverse events or unintended effects in each study condition (including summary measures, effect size estimates, and confidence intervals)	N/A	
DISCUSSION				
Interpretation	20	Interpretation of the results, taking into account study hypotheses, sources of potential bias, imprecision of measures, multiplicative analyses, and other limitations or weaknesses of the study	Y	5-6
		Discussion of results taking into account the mechanism by which the intervention was intended to work (causal pathways) or alternative mechanisms or explanations	Y	5
		Discussion of the success of and barriers to implementing the intervention, fidelity of implementation	N/A	
		Discussion of research, programmatic, or policy implications	Y	5
Generalizability	21	Generalizability (external validity) of the trial findings, taking into account the study population, the characteristics of the intervention, length of follow-up, incentives, compliance rates, specific sites/settings involved in the study, and other contextual issues	Y	5-6
Overall Evidence	22	General interpretation of the results in the context of current evidence and current theory	Y	5-6

From: Des Jarlais, D. C., Lyles, C., Crepaz, N., & the Trend Group (2004). Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: The TREND statement. *American Journal of Public Health*, 94, 361-366. For more information, visit: http://www.cdc.gov/trendstatement/